Search
News & Events
Vaccine trial aims to curb ‘superbug’Sarah Le Roi knows well how debilitating Clostridium difficile infection (CDI) can be. She was struck down with the 'superbug' while on holiday in the US.
News & Events
Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014.Genetic and functional studies of leishmaniasis: understanding the role of HLA
News & Events
Large-scale study uncovers a single major genetic risk factor for fatal parasitic diseaseResearch has identified a critical genetic risk factor for a potentially fatal parasitic disease that affects up to 400 thousand people a year, mostly children.
News & Events
Infectious Disease & Vaccination Public SeminarHear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond
News & Events
Pneumonia rates improve in Aboriginal childrenNew research from The Kids for Child Health Research shows that the pneumococcal vaccine program has contributed to closing of the gap
News & Events
WANTED: 'Flu BustersHundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.
News & Events
Bird flu vaccine produces promising resultsAn Australian-developed vaccine that's been trialed in Perth has been found to produce a strong immune response against the H5N1 bird flu virus.
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Research
Statistical considerations for the platform trial in COVID-19 vaccine priming and boostingThe Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.